23andMe Partners With Pfizer to Research Genetics of Inflammatory Bowel Disease

23andMe Partners With Pfizer to Research Genetics of Inflammatory Bowel Disease
California-based personal genetics company 23andMe recently partnered with Pfizer to enroll 10,000 patients with Inflammatory Bowel Disease in a research initiative that will explore how genetics and environment are associated with patients’ response to treatments for the disease, as well as how they relate to IBD risk and progression. Researchers conducting the study plan to leverage the

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *